Stay updated on Psoriasis Treatment Efficacy in Moderate-Severe Clinical Trial
Sign up to get notified when there's something new on the Psoriasis Treatment Efficacy in Moderate-Severe Clinical Trial page.

Latest updates to the Psoriasis Treatment Efficacy in Moderate-Severe Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study information regarding ixekizumab for psoriasis, which included study design, participant criteria, and treatment protocols. Additionally, a new identifier for Eli Lilly and Company has been added.SummaryDifference11%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.4%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.4%
Stay in the know with updates to Psoriasis Treatment Efficacy in Moderate-Severe Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Psoriasis Treatment Efficacy in Moderate-Severe Clinical Trial page.